The MaxCyte® Minute™ provides regular updates on scalable transfection of ion channels, GPCRs, and other targets for cell-based assays using the MaxCyte® STX™ Scalable Transient Transfection System. This issue, features MaxCyte's poster from LabAutomation2010 titled, Rapid, Automated Development of Cell-Based Assays for Screening GPCRs, Ion Channels and other Target Molecules Using the MaxCyte® STX™ Scalable Transfection System, along with an introduction to the newest members of our sales and business development team in North America and Europe.

The MaxCyte® STX™ Scalable Transient Transfection System can help you develop assays faster, design and conduct more physiologically relevant assays, and improve the productivity of your laboratory. Increased productivity in drug discovery campaigns can increase your likelihood of finding successful drug candidates.

Please contact us if you would like additional information about a demonstration of the MaxCyte® STX™ Scalable Transfection System in your laboratory.

Rapid, Automated Development of Cell-Based Assays for Screening GPCRs, Ion Channels and other Target Molecules Using the MaxCyte® STX™ Scalable Transfection System

At LabAutomation2010, MaxCyte was pleased to have the opportunity to present a poster demonstrating the application of the MaxCyte® STX™ Scalable Transfection System for screening single and multi-subunit ion channels, GPCRs and other molecules in HEK 293 and CHO cells. Cells transfected with the MaxCyte STX can be analyzed using automated electrophysiology, dye flux, high content screening instruments, and other methodologies that are commonly used for high throughput drug screening and drug discovery applications. Loading conditions are optimized at a small scale (static scale), and the transfection process can be scaled up using flow electroporation (large scale) without altering transfection efficiency, viability, or assay performance. Transfected cells can be used immediately or aliquoted and cryopreserved for future assay applications. Through the use of flow electroporation, MaxCyte STX users can eliminate the costly, time consuming and labor intensive process of stable cell line development by transiently transfecting target and/or reporter molecules into cell lines and physiologically relevant primary cells or stem cells.

To view the poster full size, please click here.

Erik Jans Business Development Manager - Europe Erik Jans has ten years' experience in sales and management in the drug discovery area, with expertise in assay technologies for cell signaling pathways. Erik holds a License in Molecular Biology from the Univ of Brussels and has followed a supplementary Master in Medical & Pharmaceutical Drug Development. MaxCyte's European-based customers may contact Erik on +32 474 878286 or erikj@maxcyte.com, or by clicking here.

Anthony Maniscalco North American Sales Manager Anthony Maniscalco has held sales and sales management positions with research capital equipment and reagent companies for over twenty years. He brings with him over thirteen years of experience in the transfection market, servicing pharmaceutical and academic accounts. Anthony has a BA in Chemistry from Colgate Univ. Our North American MaxCyte STX customers may contact Anthony on 919-455-4213 or amanis@maxcyte.com, or by clicking here.